tradmap

DYN Earnings Dyne Therapeutics, Inc.

Reported EPS, revenue and net income by fiscal period (SEC EDGAR) — quarterly and annual. Full financials → Chart & overview → Updated

Annual results

Diluted EPS (annual)
-$4 -$2 $0 2021 2022 2023 2024 2025
EPS
Net income (annual)
-$149M -$75M $0 2019 2020 2021 2022 2023 2024 2025
Net income
Return on equity (annual)
-106% -53% 0% 2019 2020 2021 2022 2023 2024 2025
ROE

Quarterly results

Diluted EPS (quarterly)
-$3 -$1 $0 Q3 '22 Q2 '23 Q1 '24 Q3 '24 Q2 '25 Q1 '26
EPS
Net income (quarterly)
-$179M -$89M $0 Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
Net income
Return on equity (quarterly)
-73% -36% 0% Q3 '23 Q1 '24 Q3 '24 Q1 '25 Q3 '25 Q1 '26
ROE

Reported EPS history

1–21 of 21
Q2 20262026-06-30-1.812026-07-2910-Q
Q1 20262026-03-31-0.732026-05-1110-Q
FY 20252025-12-31-3.472026-03-0210-K
Q3 20252025-09-30-2.742025-11-0510-Q
Q2 20262025-06-30-2.022026-07-2910-Q
Q1 20262025-03-31-1.052026-05-1110-Q
FY 20252024-12-31-3.372026-03-0210-K
Q3 20252024-09-30-2.492025-11-0510-Q
Q2 20252024-06-30-1.512025-07-2810-Q
Q1 20252024-03-31-0.812025-05-0810-Q
FY 20252023-12-31-3.952026-03-0210-K
Q3 20242023-09-30-2.862024-11-1210-Q
Q2 20242023-06-30-1.882024-08-1210-Q
Q1 20242023-03-31-0.782024-05-0210-Q
FY 20242022-12-31-3.232025-02-2710-K
Q3 20232022-09-30-2.502023-10-3010-Q
Q2 20232022-06-30-1.702023-08-0310-Q
Q1 20232022-03-31-0.692023-05-1110-Q
FY 20222021-12-31-2.932023-03-0210-K
Q3 20222021-09-30-1.922022-11-0310-Q
Q2 20222021-06-30-1.092022-08-0410-Q

Source: SEC EDGAR / XBRL (reported actuals; no consensus estimates). Some issuers (e.g. mortgage REITs, banks) don't report a conventional revenue line, so those charts may be omitted. Informational only — not financial advice.